Makoto Mitsunaga

TL;DR: A new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors is developed.

TL;DR: A rapidly activatable, cancer-selective fluorescence imaging probe that fluoresces upon cleavage by a cancer-specific enzyme and can be used during surgical or endoscopic tumor removal procedures, and several other aminopeptidase–based reagents identified by the authors could help surgeons to track down tiny tumors dispersed throughout body cavities.

TL;DR: Eighty percent of the A431 tumors were eradicated with repeated PIT without apparent side effects and survived tumor-free for more than 120 days even after stopping therapy at day 30, suggesting PIT is a promising highly selective and clinically feasible theranostic method for treatment of mAb-binding tumors with minimal off-target effects.

TL;DR: An activatable monoclonal antibody-fluorophore conjugate consisting of a humanized anti-Prostate-Specific Membrane Antigen (PSMA) antibody linked to an indocyanine green (ICG) derivative demonstrates promise as a method to image the extent of prostate cancer in vivo and could assist with real-time resection of extracapsular extension of tumor and positive lymph nodes.

TL;DR: Indocyanine green (ICG) has the desirable properties of having both EPR effects and rapid clearance for the real‐time endoscopic detection of tiny ovarian cancer peritoneal implants compared to a control macromolecular agent with theoretically better E PR effects but longer circulatory retention.